Biotech Co.*

Pharma Co. (Country)

Change from original agreement

Terms/Details (Date)

Angiotech Pharmaceuticals
(Canada; ANPI; TSE:ANP)

Baxter Healthcare Corp.

Expanded alliance giving Baxter the right to manufacture CoSeal and Adhibit

In February, Angiotech gave Baxter worldwide sales, marketing and distribution rights for CoSeal and Adhibit (4/21)

(Switzerland; FSE:CYTZn)

Novartis Pharma AG (Switzerland)

Extended research and licensing option agreement for vaccines for allergy, rheumatoid arthritis and chronic nervous system disorders

Terms of the extension were not disclosed; the agreement began in October 2001 (4/28)

Hemispherx Biopharma Inc. (AMEX:HEB)

Integrated Commercial Systems

Expanded agreement for the distribution of Alferon N injection in North America

Further details were not disclosed (4/22)

Ligand Pharmaceuticals

Eli Lilly and Co.

Extended collaboration to develop peroxisome proliferation activated receptor modulators for Type II diabetes, cardiovascular disorders and possibly other metabolic diseases

The deal originally was signed in 1997 (5/9)

(Sweden; SSE:PYROA)

Corbett Research Pty. Ltd. (Australia) of thermocycling and sample preparation products

Extended distribution agreement for Corbett's line

The agreement covers Germany, France and Scandinavia (4/10)

The Medicines

AstraZeneca plc (UK)

Exercised option giving The Medicines Co. exclusive worldwide rights, except for Japan, to clevidipine

It will develop the product in perioperative hypertension Phase III trials (5/19)

Vicuron Pharmaceuticals

Novartis AG (Switzerland)

Extended oral antibacterial collaboration

The collaboration is extended for two years; it is focused on a new antibiotic class for community-based market peptide deformylase inhibitors (3/27)


Applied Genetics Inc. Dermatics*

Elan Corp. plc (Ireland)

Terminated agreement for T4N5 Liposome Lotion

Applied Genetics regained all rights with the termination of the Dimericine Development Corp. joint venture with Elan; Elan sold its portion of the partnership, but remains a shareholder of Applied Genetics (4/16)

Curis Inc.

Elan Corp. plc (Ireland)

Terminated joint venture for neurological disorder compounds

Curis gained Elan's 19.9% interest in the venture in exchange for a percentage of income derived from the sale or licensing of certain neurological disorder compounds; Elan exchanged its Curis preferred stock for about 2.9M common shares in Curis (5/16)

Inex Pharmaceuticals Corp. (Canada; TSE:IEX)

Elan Corp. plc (Ireland)

Terminated agreement for Onco TCS

Inex regained full owndership of the anti-cancer drug by reacquiring the 19.9% equity interest held by Elan; Inex also retains a fully paid-up license to Elan's intellectual property related to Onco TCS (4/3)

Ribozyme Pharmaceuticals

Elan Corp. plc (Ireland)

Terminated joint venture in breast cancer

Elan will transfer its 19.9% interest in Medizyme Pharmaceuticals Ltd., which was established for the development of Herzyme, to RPI in exchange for a portion of any future license fees, development revenues and royalties on commercial sales of Herzyme (4/11)

Zealand Pharma A/S* (Denmark)

Elan Corp. plc (Ireland)

Terminated Betacure joint venture to advance ZP10

Zealand regains full commercial rights to ZP10; Elan will receive a royalty on future revenues from ZP10, and remains a share- holder in Zealand (3/27)


# The information in the chart does not cover agreements between biotech companies or agricultural agreements.

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

AMEX = American Stock Exchange; FSE = Frankfurt Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange